Evidence map›Paper›PMID 28294062›Full record

ReviewCurrent neurovascular research2017

Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin.

Kenneth Maiese

Open access · greenAbstract readReview
In one paragraph

Review in Current neurovascular research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Cognitive Impairment in Multiple Sclerosis.Bioengineering (Basel, Switzerland) · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Frontiers in physiology · 2022
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Kenneth MaieseCellular and Molecular Signaling. United States.
Cellular Research (United States) · US

Funding

Impacting Oxidative Stress and Cell Injury through Novel Pathways of the Wnt GeneR01NS053946 · NINDS · WAYNE STATE UNIVERSITY · PI MAIESE, KENNETH · 2007 to 2011
$2.4M
NINDS NIH HHS R01 NS053946
6 · The paper itself

Abstract

backgroundTransient receptor potential (TRP) channels are a superfamily of ion channels termed after the trp gene in Drosophila that are diverse in structure and control a wide range of biological functions including cell development and growth, thermal regulation, and vascular physiology. Of significant interest is the transient receptor potential cation channel subfamily V member 1 (TRPV1) receptor, also known as the capsaicin receptor and the vanilloid receptor 1, that is a non-selective cation channel sensitive to a host of external stimuli including capsaicin and camphor, venoms, acid/basic pH changes, and temperature.

methodsGiven the multiple modalities that TRPV1 receptors impact in the body, we examined and discussed the role of these receptors in vasomotor control, metabolic disorders, cellular injury, oxidative stress, apoptosis, autophagy, and neurodegenerative disorders and their overlap with other signal transduction pathways that impact trophic factors.

resultsSurprisingly, TRPV1 receptors do not rely entirely upon calcium signaling to affect cellular biology, but also have a close relationship with the mechanistic target of rapamycin (mTOR), AMP activated protein kinase (AMPK), and protein kinase B (Akt) that have roles in pain sensitivity, stem cell development, cellular survival, and cellular metabolism. These pathways with TRPV1 converge in the signaling of growth factors with recent work highlighting a relationship with erythropoietin (EPO). Angiogenesis and endothelial tube formation controlled by EPO requires, in part, the activation of TRPV1 receptors in conjunction with Akt and AMPK pathways.

conclusionTRPV1 receptors could prove to become vital to target disorders of vascular origin and neurodegeneration. Broader and currently unrealized implementations for both EPO and TRPV1 receptors can be envisioned for for the development of novel therapeutic strategies in multiple systems of the body.

Indexed as

AMP-Activated Protein Kinase KinasesAnimalsCalciumErythropoietinHumansNeurodegenerative DiseasesProtein KinasesSignal TransductionTOR Serine-Threonine KinasesTRPV Cation ChannelsAMP-Activated Protein Kinase KinasesCalciumErythropoietinProtein KinasesTOR Serine-Threonine KinasesTRPV1 protein, humanTRPV Cation Channelsagingaging-related disordersAktAlzheimer’s diseaseAMP activated protein kinase (AMPK)angiogenesisapoptosisautophagycardiovascular diseasediabetes mellitusendothelial cellsepidermal growth factorerythropoietinhamartin (tuberous sclerosis 1)/tuberin (tuberous sclerosis 2) (TSC1/TSC2)hyperthermiamechanistic target of rapamycin (mTOR)metabolismmTOR Complex 1 (mTORC1)mTOR Complex 2 (mTORC2)nerve growth factornicotinamidenicotinamide adenine dinucleotide (NAD+)oxidative stresspainphosphoinositide 3 –kinase (PI 3-K)programmed cell deathproline rich Akt substrate 40 kDa (PRAS40)silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1)sirtuinstem cellsthermoregulationtransient receptor potentialTRPV1vanilloid receptor 1

Identifiers

PMID28294062
PMCPMC5478459
OpenAlexW2603899500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.